Loading insider details...
Beta
Latest Form 4 (Feb 5, 2026): Grant/Award of 4,800,000 SABS shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Feb 5, 2026 | SAB Biotherapeutics, Inc. (SABS) | Grant/Award | 4,800,000 | n/a |
| Aug 28, 2025 | SAB Biotherapeutics, Inc. (SABS) | Grant/Award | 4,800,000 | n/a |
| Jul 17, 2024 | SAB Biotherapeutics, Inc. (SABS) | Grant/Award | 35,700 | n/a |
| Feb 23, 2024 | SAB Biotherapeutics, Inc. (SABS) | Grant/Award | 434,000 | n/a |
| Nov 30, 2023 | SAB Biotherapeutics, Inc. (SABS) | Purchase | 11,000 | $9.8K |
| Mar 16, 2023 | SAB Biotherapeutics, Inc. (SABS) | Grant/Award | 525,000 | n/a |
| Mar 2, 2023 | SAB Biotherapeutics, Inc. (SABS) | Other (see footnotes) | 208,600 | n/a |
| Sep 15, 2022 | SAB Biotherapeutics, Inc. (SABS) | Grant/Award | 525,000 | n/a |
| May 23, 2022 | SAB Biotherapeutics, Inc. (SABS) | Other (see footnotes) | 2,500,127 | n/a |
| Mar 19, 2022 | SAB Biotherapeutics, Inc. (SABS) | Grant/Award | 7,000 | n/a |